TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20210906

Group type: EXPERIMENTAL
Intervention: Football group (FG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Running group (RG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 50
Study: 18156881

Group type: EXPERIMENTAL
Intervention: Lower tidal volumes of 6 ml/kg and 10 cm H2O PEEP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Higher tidal volumes of 12 ml/kg ideal body weight and no positive end-expiratory pressure (PEEP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (lower tidal volumes and higher tidal volumes)
Number of subjects: 40
Study: 15696037

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound scanning (CUS) with a bolus of 1.5 to 2.4 mL of a second generation blood pool contrast agent
Number of subjects: 18
Study: 11796347

Group type: EXPERIMENTAL
Intervention: Ruprintrivir (4 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruprintrivir (8 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruprintrivir (multiple doses every 3 h, six times per day for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10363622

Group type: EXPERIMENTAL
Intervention: Caudal tramadol (1 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% plain bupivacaine (0.5 ml/kg)
Number of subjects: 40
Study: 8590268

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2209147

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6449801

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 31927518

Group type: EXPERIMENTAL
Intervention: Oral and written education using aspirin booklet
Number of subjects: 12
Study: 31098615

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) - 15% carbohydrate, 60% fat, 25% protein
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-Carbohydrate, Low-Fat Diet (HCLF) - 55% carbohydrate, 20% fat, 25% protein
Number of subjects: 11
Study: 28426359

Group type: EXPERIMENTAL
Intervention: Drop-in center linkage (n = 40)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Shelter linkage (n = 39)
Number of subjects: 79
Study: 26727825

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab 1.25 mg/0.05 mL (Avastin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonid 4 mg/0.1 mL (Kenalog)
Number of subjects: 20
Study: 23460711

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) ‐based chemotherapy with irinotecan (IRI)
Number of subjects: 123
Study: 20938766

Group type: EXPERIMENTAL
Intervention: Debrunner kyphosis angle
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Flexicurve kyphosis angle
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Flexicurve kyphosis index
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Non-radiological measures
Number of subjects: 113
Study: 19375557

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) with antiglycemic medications
Number of subjects: 1698
Study: 17298589

Group type: EXPERIMENTAL
Intervention: Nateglinide + insulin glargine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo + insulin glargine
Number of subjects: 55
Study: 15294641

Group type: EXPERIMENTAL
Intervention: Symbiotic containing Bifidobacterium animalis and inulin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 11377114

Group type: EXPERIMENTAL
Intervention: Active treatment sooner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 10719591

Group type: EXPERIMENTAL
Intervention: Cutting instruments
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-cutting instruments
Number of subjects: 100
Study: 8957747

Group type: EXPERIMENTAL
Intervention: Prednisone (3 month course)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (retrobulbar irradiation)
Number of subjects: 18
Study: 1313761

Group type: EXPERIMENTAL
Intervention: Low-fat high-fibre diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 30
Study: 3893389

Group type: EXPERIMENTAL
Intervention: Albumin infusion when COP fell below 24 cm H2O
Number of subjects: 220

Group type: COMPARATOR
Intervention: Albumin infusion when COP fell below 29 cm H2O
Number of subjects: 220
Study: 31707865

Group type: EXPERIMENTAL
Intervention: Cycling + functional electrical stimulation with interval pattern
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cycling + functional electrical stimulation with linear pattern
Number of subjects: 30
Study: 29785414

Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.05%)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 128
Study: 27130954

Group type: EXPERIMENTAL
Intervention: Consistent pairing of sounds with distinct visual objects
Number of subjects: 49

Group type: COMPARATOR
Intervention: Random pairing of sounds with distinct visual objects
Number of subjects: 49
Study: 25352870

Group type: EXPERIMENTAL
Intervention: Standard treatment guidelines (STG) intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study: 23600305

Group type: EXPERIMENTAL
Intervention: Proton-photon therapy with proton beam 220Mev, focal dose of 28-28.8 Gy-eq for 8, 5 or 3 fractions (3, 4 or 5.5 Gy-eq)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Proton-photon therapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group with local 4-dipole photon irradiation to 68-72 Gy in 12-14 fractions of 2 Gy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study: 20332612

Group type: EXPERIMENTAL
Intervention: Serenoa repens + selenium and lycopene (Profluss)
Number of subjects: 102

Group type: COMPARATOR
Intervention: S. repens alone
Number of subjects: 102
Study: 18627368

Group type: EXPERIMENTAL
Intervention: Interrupted sevoflurane administration (SevoI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Propofol-only (P)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous sevoflurane administration (SevoC)
Number of subjects: 42
Study: 16173137

Group type: EXPERIMENTAL
Intervention: PYY infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Jejunal feeding
Number of subjects: 8
Study: 12079004

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 10451167

Group type: EXPERIMENTAL
Intervention: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d) plus Oral Rehydration Therapy (ORT) (500 mL initially, followed by 250 mL after each subsequently passed unformed stool, up to 1,000 mL per 24 hours)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d)
Number of subjects: 80
Study: 7575286

Group type: EXPERIMENTAL
Intervention: Oral fluconazole
Number of subjects: 196

Group type: COMPARATOR
Intervention: Topical antifungals (nystatin and amphotericin B suspensions)
Number of subjects: 196
Study: 2154513

Group type: EXPERIMENTAL
Intervention: Low‐fat, low‐cholesterol diet (LFLC)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low‐fat, low‐cholesterol diet plus 50 gm/day oat bran (LFLC + OB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 50 gm/day oat bran supplemented diet (OB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 42.5 gm/day processed oat bran (POB)
Number of subjects: 71
Study: 30295811

Group type: EXPERIMENTAL
Intervention: Vedolizumab induction
Number of subjects: 895

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 895
Study: 30302465

Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg d‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ubiquinone (200 mg d‐1)
Number of subjects: 10
Study: 26410819

Group type: EXPERIMENTAL
Intervention: Lower body static stretching (SS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower body dynamic stretching (DS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper body static stretching (SS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic ROM and muscle force and activation variables
Number of subjects: 0
Study: 25193889

Group type: EXPERIMENTAL
Intervention: Arthroscopic distal clavicle resection (DCR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No additional intervention (Control group)
Number of subjects: 78
Study: 22795238

Group type: EXPERIMENTAL
Intervention: Lidocain 1% adjunction
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Bupivacain 0.25% adjunction
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intra-articular contrast injection only
Number of subjects: 154
Study: 20519902

Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 64
Study: 18660500

Group type: EXPERIMENTAL
Intervention: AirWay Scope (AWS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 13
Study: 15591082

Group type: EXPERIMENTAL
Intervention: Viscoelastic gel
Number of subjects: 49

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 49
Study: 12860861

Group type: EXPERIMENTAL
Intervention: Severe CHF patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 45
Study: 11120532

Group type: EXPERIMENTAL
Intervention: Myometrial sampling at cesarean delivery
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control group (no myometrial sampling)
Number of subjects: 354
Study: 8890060

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with expanded Polytetrafluoroethylene barrier membranes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional therapy (debridement only)
Number of subjects: 10
Study: 1503621

Group type: EXPERIMENTAL
Intervention: Cyclosporin-A (CsA)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG) with prednisone (PDN)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sequential immunosuppressive therapy (alternative therapy after no or minimal response)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count (ANC) at entry
Number of subjects: 116
Study: 6366617

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg every three weeks for two years)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30999957

Group type: EXPERIMENTAL
Intervention: LLIN + IRS
Number of subjects: 34458

Group type: EXPERIMENTAL
Intervention: LLIN
Number of subjects: 34458

Group type: EXPERIMENTAL
Intervention: IRS
Number of subjects: 34458

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34458

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 34458
Study: 30144169

Group type: EXPERIMENTAL
Intervention: Facilitated tucking (FT)
Number of subjects: 50
Study: 26894180

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 29
Study: 25068219

Group type: EXPERIMENTAL
Intervention: Glutamate injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 15
Study: 21685792

Group type: EXPERIMENTAL
Intervention: Topical diltiazem cream
Number of subjects: 134

Group type: COMPARATOR
Intervention: Botulinum toxin A (BTA)
Number of subjects: 134
Study: 19708174

Group type: EXPERIMENTAL
Intervention: Metformin therapy throughout pregnancy
Number of subjects: 59

Group type: COMPARATOR
Intervention: No metformin therapy throughout pregnancy (Control)
Number of subjects: 59
Study: 17977295

Group type: EXPERIMENTAL
Intervention: Daily topical applications of a dental cream containing CPP‐ACP (Topacal) for 3 months followed by a 3‐month period of daily toothbrushing with fluoridated dentifrice.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Daily 0.05% sodium fluoride mouthwash combined with fluoridated dentifrice for 6 months.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both interventions (CPP‐ACP and fluoride mouthwash)
Number of subjects: 26
Study: 15903281

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no supplementary medication)
Number of subjects: 43
Study: 12553505

Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg a day)
Number of subjects: 272
Study: 9623748

Group type: EXPERIMENTAL
Intervention: Sophisticated simulator group (feigned impairment with TBI information)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Naive simulator group (feigned impairment without TBI information)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (instructed to perform optimally)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TBI subjects (completed neuropsychological evaluations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Discriminate function analysis cutting score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Previously investigated cutting scores
Number of subjects: 60
Study: 8593196

Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study: 2540392

Group type: EXPERIMENTAL
Intervention: Sprint Intervals (SI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endurance (E)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination (C)
Number of subjects: 25
Study: 1198015

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block with 10 ml of 0.5% Marcaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra articular hydrocortisone injection (50 mg of hydrocortisone acetate into the glenohumeral joint)
Number of subjects: 0
Study: 31708295

Group type: EXPERIMENTAL
Intervention: MRI with systematic and targeted biopsy
Number of subjects: 273

Group type: COMPARATOR
Intervention: 12-core systematic sampling (non-MRI)
Number of subjects: 273
Study: 30095747

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 0
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels across all days
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 2
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 1
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels
Number of subjects: 549
Study: 28962661

Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract (250 mg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract (500 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (lactose monohydrate)
Number of subjects: 210
Study: 26383034

Group type: EXPERIMENTAL
Intervention: Body acupuncture (Shuigou GV 26, Neiguan PC 6, and Zusanli ST 36)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fluoxetine and minimal nontraditional acupuncture (minimally active penetrating)
Number of subjects: 68
Study: 22510162

Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Upper Limbs (FST-UL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Lower Limbs (FST-LL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 58
Study: 21533539

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 81
Study: 18081747

Group type: EXPERIMENTAL
Intervention: Desloratadine combined with dipyridamole
Number of subjects: 64

Group type: COMPARATOR
Intervention: Desloratadine only (Control)
Number of subjects: 64
Study: 15871313

Group type: EXPERIMENTAL
Intervention: Topical eutectic mixture of local anesthetics (EMLA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Topical lidocaine (LMX)
Number of subjects: 64
Study: 12587324

Group type: EXPERIMENTAL
Intervention: Combination of nebivolol and enap
Number of subjects: 0
Study: 10627088

Group type: EXPERIMENTAL
Intervention: Temazepam (TMZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-Letter Cancellation Task (3-LCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance of Wakefulness Test (MWT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple Sleep Latency Test (MSLT)
Number of subjects: 0
Study: 8560052

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no SNP)
Number of subjects: 30
Study: 1785245

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 39
Study: 7037505

Group type: EXPERIMENTAL
Intervention: Nine daily injections of fast‐acting insulin for ten days (group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional treatment with one or two daily doses of insulin (group A)
Number of subjects: 15
Study: 30407055

Group type: EXPERIMENTAL
Intervention: Behavioral app (Boost Me)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive app (Thought Challenger)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 30
Study: 28408018

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1200
Study: 25248020

Group type: EXPERIMENTAL
Intervention: Short-Term Inpatient Psychotherapy based on Transactional Analysis (STIP-TA)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Other Psychotherapies (OP)
Number of subjects: 134
Study: 24331115

Group type: EXPERIMENTAL
Intervention: DHEA 75 mg daily for 12 weeks
Number of subjects: 208

Group type: COMPARATOR
Intervention: IVF‐ICSI without DHEA supplementation
Number of subjects: 208
Study: 20934683

Group type: EXPERIMENTAL
Intervention: Touchpad (familiar input device)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mini-joystick (unfamiliar input device)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practice (for novices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Touchpad
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mini-joystick
Number of subjects: 0
Study: 19609178

Group type: EXPERIMENTAL
Intervention: 4-week behaviorally based intervention delivered in four 2-hour segments
Number of subjects: 122
Study: 17556705

Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable consumption
Number of subjects: 4652

Group type: EXPERIMENTAL
Intervention: DASH diet scores
Number of subjects: 4652

Group type: COMPARATOR
Intervention: Dairy products and Keys score
Number of subjects: 4652
Study: 15455733

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg B.I.D. with scaling and root planing (SRP)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP)
Number of subjects: 210
Study: 11306234

Group type: EXPERIMENTAL
Intervention: BV treatment in high-risk women (previous preterm delivery)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: BV treatment in high-risk women (not having BV)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Routine BV screening and treatment
Number of subjects: 7
Study: 9806702

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 20
Study: 8747858

Group type: EXPERIMENTAL
Intervention: Patients with late-onset Alzheimer's disease carrying allele epsilon 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with early-onset Alzheimer's disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with Parkinson's disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals over 60 years
Number of subjects: 0
Study: 2465708

Group type: EXPERIMENTAL
Intervention: 0.015 microgram.kg‐1 pentamorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.03 microgram.kg‐1 pentamorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.06 microgram.kg‐1 pentamorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.12 microgram.kg‐1 pentamorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.24 microgram.kg‐1 pentamorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.48 microgram.kg‐1 pentamorphone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 811237

Group type: EXPERIMENTAL
Intervention: Intramuscular and oral bromhexine for 5 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no bromhexine)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intramuscular and oral bromhexine for 5 days in high-risk patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (high-risk patients)
Number of subjects: 70
Study: 30716557

Group type: EXPERIMENTAL
Intervention: Bodies in Motion program
Number of subjects: 97

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 97
Study: 28988168

Group type: EXPERIMENTAL
Intervention: Decision aid with information on overdetection
Number of subjects: 811

Group type: COMPARATOR
Intervention: Decision aid without information on overdetection
Number of subjects: 811
Study: 25331270

Group type: EXPERIMENTAL
Intervention: Red Bull Energy drink (caffeine at 2 mg/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoenergetic, isovolumetric, noncaffeinated control drink (CD)
Number of subjects: 20